Home › NCT07168915

A Study of V118E in Healthy Participants (V118E-003)

A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults

Who can join

Ages 18 to 49 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

\- Is in good health before randomization

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases

About the study

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria.

PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria.

The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

What is being tested

• V118E (biological)
• PREVNAR 20™ (biological)
• Saline (biological)

Sponsor: Merck Sharp & Dohme LLC · Participants: 126 · Started: Oct 8, 2025

Contact the study team

• Toll Free Number · Phone: 1-888-577-8839

Official record on ClinicalTrials.gov — NCT07168915

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.